This “Rheumatoid Arthritis- Pipeline Insight, 2022” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Rheumatoid Arthritis is called an autoimmune condition. It starts when your immune system, which is supposed to protect you, goes awry and begins to attack your body's own tissues. It causes inflammation in the lining of your joints (the synovium). As a result, joints may get red, warm, swollen, and painful. RA affects joints on both sides of the body, such as both hands, both wrists, and both knees. This symmetry helps to set it apart from other types of arthritis. Over time, RA can affect other body parts and systems, from eyes to heart, lungs, skin, blood vessels, and more. The warning signs of RA are: Joint pain and swelling Stiffness, especially in the morning, Fatigue. Rheumatoid arthritis affects everyone differently. For some, joint symptoms happen gradually over several years. In others, it may come on quickly. Some people may have rheumatoid arthritis for a short time and then go into remission, which means they don't have symptoms. The disease is two to three times more common in women than in men, but men tend to have more severe symptoms. It usually starts in middle age. But young children and the elderly also can get it. The exact cause of Rheumatoid Arthritis is still not known. Something seems to trigger the immune system to attack joints and, sometimes, other organs. Some experts think a virus or bacteria may change immune system, causing it to attack joints. Certain genetic patterns may make some people more likely to get RA than others. Rheumatoid arthritis is diagnosed from a combination of things, including: The location and symmetry of painful joints, especially the hand joints, Joint stiffness in the morning, Bumps and nodules under the skin (rheumatoid nodules) and Results of X-rays and blood tests.
"Rheumatoid Arthritis- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ozoralizumab: Taisho Pharmaceutical
Ozoralizumab (ATN-103) is a trivalent humanized low molecular weight compound that combines two anti-TNFα NANOBODY® VHHs and one anti-serum albumin NANOBODY® VHH. Ozoralizumab is about a quarter of the size of conventional IgG antibodies. Ozoralizumab binds to two subunits of TNFα and potently neutralizes its action. Ozoralizumab, initially discovered by Ablynx. In March 2021, Taisho announced that it submitted an application for approval to manufacture and market the anti-TNFα NANOBODY® therapeutic (generic name: ozoralizumab) to the Ministry of Health, Labour and Welfare for rheumatoid arthritis (RA).
ABX 464 : Abivax
ABX464 is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA, called miR-124, with potent anti-inflammatory properties. ABX464 showed a very favorable tolerability profile with mainly mild to moderate and transient side effects.
Ianalumab:Novartis
Ianalumab is an anti-B-cell activating factor (BAFF) receptor antibody which is administered subcutaneously. The drug is being investigated in Phase 2 stage of development for the treatment of Rheumatoid Arthritis.
BAY1830839:Bayer
BAY 1830839 is a novel small molecule inhibitor of IRAK4 identified by a medicinal chemistry optimization program. Key features of the compound are high potency (IC50 of 3 nM) in a biochemical assay, excellent kinase selectivity and a good overall PK profile making the compound a valuable tool for in vivo studies. The drug is being investigated in Phase 1 stage of development for the treatment of Rheumatoid Arthritis.
This segment of the report provides insights about the different Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 120+ key companies which are developing the therapies for Rheumatoid Arthritis. The companies which have their Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. phase III include, Taisho Pharmaceutical
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis drugs.
This product will be delivered within 1-3 business days.
Geography Covered
- Global coverage
Rheumatoid Arthritis Understanding
Rheumatoid Arthritis: Overview
Rheumatoid Arthritis is called an autoimmune condition. It starts when your immune system, which is supposed to protect you, goes awry and begins to attack your body's own tissues. It causes inflammation in the lining of your joints (the synovium). As a result, joints may get red, warm, swollen, and painful. RA affects joints on both sides of the body, such as both hands, both wrists, and both knees. This symmetry helps to set it apart from other types of arthritis. Over time, RA can affect other body parts and systems, from eyes to heart, lungs, skin, blood vessels, and more. The warning signs of RA are: Joint pain and swelling Stiffness, especially in the morning, Fatigue. Rheumatoid arthritis affects everyone differently. For some, joint symptoms happen gradually over several years. In others, it may come on quickly. Some people may have rheumatoid arthritis for a short time and then go into remission, which means they don't have symptoms. The disease is two to three times more common in women than in men, but men tend to have more severe symptoms. It usually starts in middle age. But young children and the elderly also can get it. The exact cause of Rheumatoid Arthritis is still not known. Something seems to trigger the immune system to attack joints and, sometimes, other organs. Some experts think a virus or bacteria may change immune system, causing it to attack joints. Certain genetic patterns may make some people more likely to get RA than others. Rheumatoid arthritis is diagnosed from a combination of things, including: The location and symmetry of painful joints, especially the hand joints, Joint stiffness in the morning, Bumps and nodules under the skin (rheumatoid nodules) and Results of X-rays and blood tests.
"Rheumatoid Arthritis- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis.
Rheumatoid Arthritis Emerging Drugs Chapters
This segment of the Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rheumatoid Arthritis Emerging Drugs
Ozoralizumab: Taisho Pharmaceutical
Ozoralizumab (ATN-103) is a trivalent humanized low molecular weight compound that combines two anti-TNFα NANOBODY® VHHs and one anti-serum albumin NANOBODY® VHH. Ozoralizumab is about a quarter of the size of conventional IgG antibodies. Ozoralizumab binds to two subunits of TNFα and potently neutralizes its action. Ozoralizumab, initially discovered by Ablynx. In March 2021, Taisho announced that it submitted an application for approval to manufacture and market the anti-TNFα NANOBODY® therapeutic (generic name: ozoralizumab) to the Ministry of Health, Labour and Welfare for rheumatoid arthritis (RA).
ABX 464 : Abivax
ABX464 is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA, called miR-124, with potent anti-inflammatory properties. ABX464 showed a very favorable tolerability profile with mainly mild to moderate and transient side effects.
Ianalumab:Novartis
Ianalumab is an anti-B-cell activating factor (BAFF) receptor antibody which is administered subcutaneously. The drug is being investigated in Phase 2 stage of development for the treatment of Rheumatoid Arthritis.
BAY1830839:Bayer
BAY 1830839 is a novel small molecule inhibitor of IRAK4 identified by a medicinal chemistry optimization program. Key features of the compound are high potency (IC50 of 3 nM) in a biochemical assay, excellent kinase selectivity and a good overall PK profile making the compound a valuable tool for in vivo studies. The drug is being investigated in Phase 1 stage of development for the treatment of Rheumatoid Arthritis.
Rheumatoid Arthritis: Therapeutic Assessment
This segment of the report provides insights about the different Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Rheumatoid Arthritis
There are approx. 120+ key companies which are developing the therapies for Rheumatoid Arthritis. The companies which have their Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. phase III include, Taisho Pharmaceutical
Phases
This report covers around 120+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Rheumatoid Arthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis drugs.
Rheumatoid Arthritis Report Insights
- Rheumatoid Arthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Rheumatoid Arthritis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Rheumatoid Arthritis drugs?
- How many Rheumatoid Arthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rheumatoid Arthritis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rheumatoid Arthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Rheumatoid Arthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Abivax
- Kymera Therapeutics
- Akari Therapeutics
- Sierra Oncology
- Neutrolis Therapeutics
- Centivax
- Taisho
- Hope Biosciences
- UCB
- Galmed Pharmaceuticals
- Celon Pharma
- Jiangsu Hengrui Medicine Co.
- Cyxone
- Oryn Therapeutics
Key Products
- ABX464
- KT 474
- Nomacopan
- Momelotinib
- NTR 441
- Anti-CXCR5 antibody
- Ozoralizumab
- HB adMSCs
- Amilo-5MER
- CPL-409116
- SHR 0302
This product will be delivered within 1-3 business days.
Table of Contents
IntroductionExecutive Summary
Rheumatoid Arthritis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Rheumatoid Arthritis- Analytical Perspective
Late Stage Products (Pre-Registration)
- Comparative Analysis
Ozoralizumab : Taisho Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
ABX464 : Abivax
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
BAY1830839: Bayer
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drugname: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Rheumatoid Arthritis Key Companies
Rheumatoid Arthritis Key Products
Rheumatoid Arthritis- Unmet Needs
Rheumatoid Arthritis- Market Drivers and Barriers
Rheumatoid Arthritis- Future Perspectives and Conclusion
Rheumatoid Arthritis Analyst Views
Rheumatoid Arthritis Key Companies
AppendixList of Tables
Table 1 Total Products for Rheumatoid Arthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Rheumatoid Arthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abivax
- Kymera Therapeutics
- Akari Therapeutics
- Sierra Oncology
- Neutrolis Therapeutics
- Centivax
- Taisho
- Hope Biosciences
- UCB
- Galmed Pharmaceuticals
- Celon Pharma
- Jiangsu Hengrui Medicine Co.
- Cyxone
- Oryn Therapeutics
